ArticleJournal of diabetes2024
The combined effect of triglyceride-glucose index and high-sensitivity C-reactive protein on cardiovascular outcomes in patients with chronic coronary syndrome: A multicenter cohort study.
Article in Journal of diabetes, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The Machine Learning Models in Major Cardiovascular Adverse Events Prediction Based on Coronary Computed Tomography Angiography: Systematic Review.Journal of medical Internet research · 2025Pooled it
- Associations between multiple metabolic indices and circadian syndrome: a cross-sectional study with mediation analysis of the C-reactive protein triglyceride glucose index.Hormones (Athens, Greece) · 2026Article
- Associations of cumulative exposure and dynamic patterns of the C-reactive protein-triglyceride-glucose index with cardiometabolic multimorbidity in middle-aged and elderly Chinese: a nationwide cohort study.BMC public health · 2026Article
- 10-year cardiovascular disease risk and its contributing factors in primary hyperparathyroidism.Endocrine · 2026Article
- Prognostic Value of Composite Biomarkers Integrating Insulin Resistance and Coronary Inflammation for Major Adverse Cardiovascular Events in Post-PCI Patients with Coronary Artery Disease Across Glycemic Status: A Prospective Cohort Study.Journal of inflammation research · 2026Article
- The Association of C-Reactive Protein-Triglyceride Glucose Index with Major Adverse Cardiovascular Events in Patients with Acute Myocardial Infarction.Journal of inflammation research · 2026Article
- The joint association of insulin resistance index and neutrophil percentage to albumin ratio with acute kidney injury after orthopedic surgery: a retrospective cohort study.Frontiers in nutrition · 2026Article
- Triglyceride glucose index predicts long-term mortality and major adverse cardiovascular events in patients with type 2 diabetes.Cardiovascular diabetology · 2025Article
- Mechanistic exploration of obesity-related indicators and motor cognitive risk syndrome: a mediated effect based on C-reactive protein triglyceride glucose index.Frontiers in aging neuroscience · 2025Article
- Observational
- The comprehensive effects of high-sensitivity C-reactive protein and triglyceride glucose index on cardiometabolic multimorbidity.Frontiers in endocrinology · 2025Article
- Predicting high sensitivity C-reactive protein levels and their associations in a large population using decision tree and linear regression.Scientific reports · 2024Article
- The combined effect of triglyceride-glucose index and high-sensitivity C-reactive protein on cardiovascular outcomes in patients with chronic coronary syndrome: A multicenter cohort study.Journal of diabetes · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
Abstract
backgroundThe triglyceride-glucose (TyG) index and high-sensitivity C-reactive protein (hsCRP) are the commonly used biomarkers for insulin resistance and systemic inflammation, respectively. We aimed to investigate the combined association of TyG and hsCRP with the major adverse cardiovascular events (MACE) in patients with chronic coronary syndrome (CCS).
methodsA total of 9421 patients with CCS were included in this study. The primary endpoint was defined as a composite of MACE covering all-cause death, nonfatal myocardial infarction, and revascularization.
resultsDuring the 2-year follow-up period, 660 (7.0%) cases of MACE were recorded. Participants were divided equally into three groups according to TyG levels. Compared with the TyG T1 group, the risk of MACE was significantly higher in the TyG T3 group. It is noteworthy that among patients in the highest tertile of TyG, hsCRP >3 mg/L was significantly associated with an increased risk of MACE, whereas the results were not significant in the medium to low TyG groups. When patients were divided into six groups according to hsCRP and TyG, the Cox regression analysis showed that patients in the TyG T3 and hsCRP >3 mg/L group had a significantly higher risk of MACE than those in the TyG T1 and hsCRP ≤3 mg/L group. However, no significant interaction was found between TyG and hsCRP on the risk of MACE.
conclusionOur study suggests that the concurrent assessment of TyG and hsCRP may be valuable in identifying high-risk populations and guiding management strategies among CCS patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.